Internal Medicine, Hematology & Oncology · Philadelphia, PA
NPI
1467687392
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
333 Cottman Ave
Philadelphia, PA, 19111
Phone (215) 728-2500
Groups this clinician bills Medicare through
Medicare paid, 2024
$33K
380 services
Medicare patients, 2024
189
Average age 74
Drug cost, 2024
$4.6M
852 prescriptions
Company payments, 2025
$6,446
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jason A Incorvati was code 99214 (office e&m - established), 163 times for 112 patients. In total Jason A Incorvati billed 380 services in 10 codes, and Medicare paid $33K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-04-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 163 | 112 | $66.38 | $11K |
| 99215 Office E&M - Established | Facility | 76 | 42 | $104.13 | $7,914 |
| 99214 Office E&M - Established | Office | 62 | 46 | $104.80 | $6,498 |
| 99204 Office E&M - New | Facility | 23 | 23 | $97.99 | $2,254 |
| 99213 Office E&M - Established | Facility | 16 | 15 | $36.52 | $584 |
By year: 2022 $38K for 477 services; 2023 $27K for 354 services; 2024 $33K for 380 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jason A Incorvati prescribed most often to Medicare patients was Anastrozole, with 191 prescriptions and refills. In total Jason A Incorvati wrote 852 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 191 | 501 | 61 | $4,763 |
| Ibrance Palbociclib | 156 | 156 | 17 | $2.5M |
| Letrozole Generic | 111 | 319 | 40 | $2,142 |
| Exemestane Generic | 54 | 149 | 19 | $6,827 |
| Verzenio Abemaciclib | 40 | 40 | Under 11 | $617K |
| Eliquis Apixaban | 27 | 35 | Under 11 | $20K |
| Hydroxyurea Generic | 24 | 57 | Under 11 | $881 |
| Revlimid Lenalidomide | 24 | 24 | Under 11 | $408K |
| Sprycel Dasatinib | 23 | 23 | Under 11 | $308K |
| Dexamethasone Generic | 23 | 23 | 11 | $342 |
| Ondansetron Hcl Generic | 13 | 15 | Under 11 | $47.59 |
| Bosulif Bosutinib | 12 | 12 | Under 11 | $178K |
| Kisqali Ribociclib Succinate | 12 | 12 | Under 11 | $197K |
| Prochlorperazine Maleate Generic | 11 | 11 | Under 11 | $105 |
Brand drugs: 325 claims; generic drugs: 527 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jason A Incorvati $6,446 ($6,446 in general payments such as food, travel and fees) from 5 companies. The largest payer was Gilead Sciences, Inc. with $5,946.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.